Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ESPR

Esperion Therapeutics Inc.

Apr 24 • 04:00PM ET

2.13

Dollar change +0.04
Percentage change 1.91	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC JFWD AVUS QQQS

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	1.10%	Shs Outstand	170.42M	Perf Week	15.76%
Market Cap	362.99M	Forward P/E	40.48	EPS next Y	0.05	Insider Trans	0.00%	Shs Float	168.54M	Perf Month	-18.70%
Income	-209.25M	PEG	-	EPS next Q	0.05	Inst Own	48.28%	Short Float	11.04%	Perf Quarter	4.93%
Sales	116.33M	P/S	3.12	EPS this Y	80.92%	Inst Trans	5.01%	Short Ratio	2.98	Perf Half Y	167.79%
Book/sh	-3.85	P/B	-	EPS next Y	113.58%	ROA	-92.23%	Short Interest	18.60M	Perf Year	74.59%
Cash/sh	0.48	P/C	4.41	EPS next 5Y	16.90%	ROE	-	52W Range	0.70 - 3.40	Perf YTD	-28.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.09%	ROI	-422.11%	52W High	-37.35%	Beta	0.86
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	7.64%	Gross Margin	62.67%	52W Low	204.29%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	1.29	EPS Y/Y TTM	40.41%	Oper. Margin	-122.46%	RSI (14)	44.32	Volatility	9.98% 11.94%
Employees	240	Debt/Eq	-	Sales Y/Y TTM	54.14%	Profit Margin	-179.87%	Recom	1.75	Target Price	7.41
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	33.60%	Payout	-	Rel Volume	0.86	Prev Close	2.09
Sales Surprise	12.58%	EPS Surprise	-3.80%	Sales Q/Q	71.38%	Earnings	May 07 BMO	Avg Volume	6.24M	Price	2.13
SMA20	-13.83%	SMA50	-12.57%	SMA200	19.47%	Trades		Volume	5,684,029	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20
Apr-26-21	Resumed	Credit Suisse	Outperform	$45
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight	$30
Feb-12-21	Downgrade	Jefferies	Buy → Hold	$30
Feb-09-21	Downgrade	Goldman	Neutral → Sell	$44 → $24

Show Previous Ratings

Apr-23-24 08:00AM	Esperion to Report First Quarter 2024 Financial Results on May 7 (GlobeNewswire) +9.42%
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-07-24 02:45PM	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity (GlobeNewswire)
Apr-01-24 08:00AM	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? (Zacks)
08:00AM	Loading…
Mar-26-24 08:00AM	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-24 04:00PM	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 (GlobeNewswire) +14.41%
Mar-22-24 06:26PM	U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (Business Wire) +8.53%
03:10PM	U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (GlobeNewswire)
11:04AM	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 08:34AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.38%
07:41AM	Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues (Zacks)
Feb-27-24 09:38PM	Q4 2023 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.27%
07:53AM	Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 (GuruFocus.com)
07:20AM	Loading…
07:20AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:25AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-16-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 03:13AM	Should You Sell Esperion Therapeutics (ESPR)? (Insider Monkey)
Feb-13-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 (GlobeNewswire)
Feb-01-24 02:00PM	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule (GlobeNewswire)
Jan-23-24 04:00PM	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-19-24 08:50AM	Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today? (InvestorPlace) -6.05%
Jan-18-24 09:15PM	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock (GlobeNewswire) -16.34%
04:00PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 07:00AM	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation (GlobeNewswire) -21.23%
Dec-18-23 08:00AM	Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.93%
04:00PM	Loading…
Dec-13-23 04:00PM	U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Dec-07-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report? (Zacks) +5.33%
Nov-13-23 10:30AM	Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-11-23 11:00AM	Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 (GlobeNewswire)
Nov-09-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -10.79%
Nov-08-23 01:16PM	Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues (Zacks)
11:04AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:19AM	Esperion Therapeutics Inc (ESPR) Reports 79% Y/Y Growth in Q3 Total Revenue (GuruFocus.com) +7.74%
07:15AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:06AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 10:01AM	Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-31-23 08:00AM	Esperion to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 08:00AM	Esperion to Report Third Quarter 2023 Financial Results on November 7 (GlobeNewswire)
Sep-12-23 10:15AM	American College of Cardiology Program to Increase Cholesterol Screenings (GlobeNewswire)
Aug-31-23 11:31AM	Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report? (Zacks)
Aug-28-23 08:00AM	Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +14.49%
Aug-26-23 11:00AM	Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 (GlobeNewswire)
Aug-11-23 08:00AM	Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-08-23 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-23 08:06AM	With 77% ownership, Esperion Therapeutics, Inc. (NASDAQ:ESPR) boasts of strong institutional backing (Simply Wall St.)
Aug-02-23 09:06AM	Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues (Zacks) +5.92%
Aug-01-23 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.64%
06:05AM	Esperion Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:00AM	Esperion Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-24-23 08:00AM	Esperion to Participate in BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-18-23 08:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire) +5.37%
Jul-17-23 06:00AM	Esperion to Report Second Quarter 2023 Financial Results on August 1 (GlobeNewswire)
Jul-07-23 08:00AM	Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 (GlobeNewswire)
Jun-28-23 08:00AM	Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
Jun-24-23 02:30PM	Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions (GlobeNewswire)
Jun-15-23 02:30PM	Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 (GlobeNewswire) +11.38%
06:27AM	Not Many Are Piling Into Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Yet As It Plummets 28% (Simply Wall St.)
Jun-08-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report? (Zacks)
08:00AM	Esperion to Present New Key Science at the American Diabetes Associations 83rd Scientific Sessions 2023 (GlobeNewswire)
Jun-07-23 09:54AM	When Will Esperion Therapeutics, Inc. (NASDAQ:ESPR) Turn A Profit? (Simply Wall St.)
Jun-05-23 08:00AM	Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023 (GlobeNewswire)
Jun-01-23 08:00AM	Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet (GlobeNewswire)
May-25-23 04:30PM	Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) -5.70%
May-24-23 08:00AM	Esperion to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 09:55AM	Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up (Zacks)
May-09-23 08:25AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.19%
07:14AM	Esperion Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Esperion Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:30AM	Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 (GlobeNewswire)
May-01-23 08:00AM	Esperion to Participate in JMP Securities Life Sciences Conference (GlobeNewswire) +7.58%
Apr-27-23 08:00AM	Esperion to Participate in Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
Apr-25-23 10:01AM	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	Esperion to Report First Quarter 2023 Financial Results May 9, 2023 (GlobeNewswire)
Apr-19-23 08:42AM	Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC (GlobeNewswire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) +7.94%
Apr-03-23 08:00AM	Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference (GlobeNewswire)
Mar-23-23 11:30AM	Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.85%
Mar-22-23 04:15PM	Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Mar-20-23 08:00AM	Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Mar-18-23 08:52AM	Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers (Simply Wall St.)
Mar-17-23 12:57PM	Esperion (ESPR) Plummets 54% Over Milestone Payment Row (Zacks) -14.84%
08:28AM	5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' \| Pro Recap (Investing.com)
Mar-16-23 08:21AM	Esperions stock tumbles after disclosing dispute about milestone payment (MarketWatch) -54.27%
Mar-10-23 11:05AM	Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why (Zacks) -5.19%
Mar-08-23 08:00AM	International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk (GlobeNewswire)
Mar-06-23 02:45PM	Alternatives to Popular Cholesterol-Lowering Drug Cut Heart-Attack Risk (The Wall Street Journal) -19.95%
01:36PM	2 Biotech Stocks Options Traders Are Watching (Schaeffer's Investment Research)
08:15AM	Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors (Benzinga)
07:45AM	China stocks slip after growth target released, as Ciena shares pop on earnings beat (MarketWatch)
07:01AM	Esperion Therapeutics stock slumps 22% premarket as data from study of cholesterol-lowering drug fail to impress investors (MarketWatch)
Mar-04-23 10:30AM	Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients (GlobeNewswire)
Feb-24-23 01:40PM	Esperion Launches New Scientific Website (GlobeNewswire) +6.35%
Feb-23-23 08:00AM	Esperion to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warren Eric	Chief Commercial Officer	Sep 20 '23	Sale	1.25	742	924	68,318	Sep 21 05:06 PM
Warren Eric	Chief Commercial Officer	Aug 18 '23	Sale	1.41	243	344	69,060	Aug 21 04:32 PM
Warren Eric	Chief Commercial Officer	Jul 19 '23	Sale	1.58	106	168	69,303	Jul 20 04:38 PM
Warren Eric	Chief Commercial Officer	Jun 21 '23	Sale	1.48	603	894	69,409	Jun 22 04:45 PM
Warren Eric	Chief Commercial Officer	May 17 '23	Sale	1.62	219	356	70,012	May 18 04:07 PM
CARROLL J MARTIN	Director	May 11 '23	Buy	1.57	23,091	36,285	36,500	May 11 04:11 PM
CARROLL J MARTIN	Director	May 10 '23	Buy	1.49	8,409	12,545	13,409	May 11 04:11 PM
ROCAMBOLI STEPHEN	Director	May 10 '23	Buy	1.50	8,111	12,126	8,111	May 11 04:10 PM
Koenig Sheldon L.	President and CEO	May 09 '23	Buy	1.26	20,000	25,192	312,816	May 10 04:12 PM

Open in Screener

EXAS

Exact Sciences Corp.

Apr 24 • 04:00PM ET

63.24

Dollar change -0.29
Percentage change -0.46	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

EXAS Exact Sciences Corp. daily Stock Chart

Held by: VTI VB VXF VBK ARKK ARKG VHT IWR FBT SCHM

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	1.04%	Shs Outstand	181.36M	Perf Week	0.03%
Market Cap	11.48B	Forward P/E	535.66	EPS next Y	0.12	Insider Trans	-5.34%	Shs Float	179.65M	Perf Month	-0.82%
Income	-204.15M	PEG	-	EPS next Q	-0.48	Inst Own	87.64%	Short Float	5.51%	Perf Quarter	-1.53%
Sales	2.50B	P/S	4.59	EPS this Y	19.50%	Inst Trans	-1.74%	Short Ratio	4.05	Perf Half Y	-1.25%
Book/sh	17.34	P/B	3.65	EPS next Y	112.98%	ROA	-3.00%	Short Interest	9.89M	Perf Year	-4.49%
Cash/sh	4.28	P/C	14.76	EPS next 5Y	-	ROE	-6.60%	52W Range	56.05 - 100.77	Perf YTD	-14.52%
Dividend Est.	-	P/FCF	359.54	EPS past 5Y	4.59%	ROI	-3.63%	52W High	-37.24%	Beta	1.24
Dividend TTM	-	Quick Ratio	2.07	Sales past 5Y	43.88%	Gross Margin	70.14%	52W Low	12.83%	ATR (14)	3.04
Dividend Ex-Date	-	Current Ratio	2.32	EPS Y/Y TTM	67.92%	Oper. Margin	-12.20%	RSI (14)	44.14	Volatility	4.05% 4.66%
Employees	6600	Debt/Eq	0.82	Sales Y/Y TTM	19.93%	Profit Margin	-8.17%	Recom	1.32	Target Price	90.49
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	61.80%	Payout	-	Rel Volume	0.50	Prev Close	63.53
Sales Surprise	1.26%	EPS Surprise	36.16%	Sales Q/Q	16.98%	Earnings	May 08 AMC	Avg Volume	2.44M	Price	63.24
SMA20	-7.33%	SMA50	-0.15%	SMA200	-10.47%	Trades		Volume	1,213,600	Change	-0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35
Aug-25-22	Initiated	Credit Suisse	Outperform	$55
Jun-03-22	Initiated	Piper Sandler	Neutral	$50
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform	$160 → $130
Jul-29-21	Reiterated	Stifel	Buy	$165 → $145
Jul-29-21	Reiterated	Oppenheimer	Outperform	$161 → $155
Jul-29-21	Reiterated	Canaccord Genuity	Buy	$185 → $160
Jul-29-21	Reiterated	BTIG Research	Buy	$155 → $145
Jun-15-21	Initiated	Raymond James	Strong Buy	$160

Show Previous Ratings

Apr-24-24 06:15PM	Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:16AM	Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) (Insider Monkey)
Apr-22-24 12:44PM	Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? (Zacks)
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-17-24 06:15PM	Why Exact Sciences (EXAS) Dipped More Than Broader Market Today (Zacks)
06:52AM	Loading…
Apr-15-24 06:52AM	Exact Sciences names Aaron Bloomer CFO (MedTech Dive) -8.40%
06:00AM	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer (Business Wire)
Apr-12-24 07:00AM	Here's Why Exact Sciences Corporation (EXAS) Declined in Q1 (Insider Monkey)
06:49AM	Should You Hold ON Semiconductor Corporation (ON)? (Insider Monkey)
06:40AM	Should You be Bullish on the Long-Term Growth of Atlassian Corporation (TEAM)? (Insider Monkey)
Apr-11-24 06:00AM	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes (Business Wire)
Apr-10-24 06:15PM	Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know (Zacks)
08:16AM	Search for Cancer Blood Test Continues Despite Illumina-Grail Deals Failure (Barrons.com)
12:00AM	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? (TipRanks)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
12:05PM	Loading…
Apr-08-24 12:05PM	Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 (Business Wire)
07:00AM	Sorry, but Blood Tests Wont Replace Stool Samples or Colonoscopies Yet (The Wall Street Journal)
06:00AM	Exact Sciences Schedules First Quarter 2024 Earnings Call (Business Wire)
Apr-05-24 10:16AM	Freenomes colorectal cancer blood test data underwhelm analysts (MedTech Dive)
Apr-04-24 10:15AM	1 Beaten-Down Cathie Wood Stock to Buy and Hold (Motley Fool)
06:05AM	Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment (Business Wire)
Apr-03-24 09:57AM	Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising (Zacks)
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Mar-29-24 08:09AM	Exact Sciences, Mayo Clinic share early data on esophageal cancer test (MedTech Dive)
Mar-28-24 06:00AM	Exact Sciences Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer (Business Wire)
Mar-27-24 08:05AM	Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner (Business Wire)
Mar-26-24 07:00AM	3 Growth Stocks to Buy at 52-Week Lows in March (InvestorPlace)
Mar-25-24 09:55AM	How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83% (Zacks)
Mar-22-24 11:30AM	Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-18-24 08:19AM	Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM (Zacks)
04:30AM	Loading…
04:30AM	Guardant posts data for colon cancer blood test amid push from rivals (MedTech Dive)
Mar-14-24 04:16PM	Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates (Investor's Business Daily)
Mar-13-24 05:03PM	The New England Journal of Medicine Publishes Cologuard Plus Test Results from Pivotal BLUE-C Study (Business Wire)
Mar-11-24 12:59AM	2 Beaten-Down Cathie Wood Stocks With Massive Potential (Motley Fool)
Mar-08-24 09:55AM	Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-07-24 07:59AM	Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer (Business Wire) +9.22%
Mar-04-24 11:52PM	Exact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 Shares (GuruFocus.com)
03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace)
10:38AM	7 Stable Stocks to Buy for 100% Returns by 2025 (InvestorPlace)
Mar-03-24 10:32AM	Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices (InvestorPlace)
Feb-26-24 06:00AM	Exact Sciences to Participate in March Investor Conference (Business Wire)
Feb-23-24 12:01PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-22-24 11:08AM	Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.00%
10:30AM	Q4 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
10:22AM	Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y (Zacks)
01:30AM	Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript (Motley Fool)
12:06AM	Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 06:20PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
05:12PM	Exact Sciences Corp Reports Robust Revenue Growth and Positive Free Cash Flow in Q4 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Fourth Quarter 2023 Results (Business Wire)
Feb-20-24 02:39AM	LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy? (TipRanks)
Feb-15-24 07:47AM	Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store? (Zacks)
Feb-14-24 10:00AM	Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-13-24 08:12PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-10-24 05:06PM	Top 5 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 09:00AM	Cathie Wood Is Selling This Stock: Should You? (Motley Fool) -5.36%
Feb-01-24 06:00AM	Exact Sciences Schedules Fourth Quarter 2023 Earnings Call (Business Wire)
Jan-28-24 09:25AM	3 Stocks to Buy for the Age of Personalized Medicine (InvestorPlace)
Jan-22-24 08:00AM	2 Cathie Wood Growth Stocks to Buy and Hold for the Long Haul (Motley Fool)
Jan-18-24 05:04AM	The Top 3 Stocks in the High-Potential Cancer Testing Market (InvestorPlace)
Jan-13-24 02:05PM	BIIB, ZTS, EXAS: Which Strong Buy Healthcare Stock is Best? (TipRanks)
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
Jan-07-24 04:30PM	Exact Sciences Announces Preliminary Fourth Quarter 2023 Results (PR Newswire)
Jan-02-24 06:00AM	Exact Sciences to participate in J.P. Morgan Healthcare Conference (PR Newswire)
Dec-21-23 09:43AM	Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid (Zacks) +6.14%
Dec-20-23 01:49PM	5 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
Dec-17-23 05:43AM	1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest (Motley Fool)
Dec-14-23 04:02AM	Ark Invest Stock Portfolio: 16 Biggest Positions (Insider Monkey)
Dec-13-23 12:52PM	Here's Why You Should Retain Exact Sciences (EXAS) Stock Now (Zacks)
08:45AM	Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? (Motley Fool)
Dec-07-23 08:05AM	Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings (PR Newswire)
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-04-23 12:13PM	Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue? (Zacks)
Dec-01-23 11:32AM	Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report? (Zacks)
05:26AM	Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3 (Insider Monkey)
Nov-30-23 04:05PM	Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients (PR Newswire)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-23-23 12:02PM	15 Stocks with Consistent Growth (Insider Monkey)
Nov-20-23 03:06PM	3 Biotech Stocks With Big-Time Breakthrough Potential (InvestorPlace)
09:55AM	Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High? (Zacks)
07:30AM	2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030 (Motley Fool)
Nov-17-23 08:04PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +8.39%
07:10AM	Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy (PR Newswire)
Nov-14-23 05:20AM	3 Stocks to Love Despite All of the Wall Street Hate (InvestorPlace) +7.07%
Nov-10-23 07:00AM	7 Biotech Stocks to Buy for Big-Time Gains (InvestorPlace)
Nov-09-23 08:10PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -5.09%
Nov-06-23 09:35AM	Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average (Zacks)
Nov-03-23 08:09PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +7.30%
Nov-02-23 07:23PM	Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:02PM	Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth (Investor's Business Daily)
11:03AM	Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises (Zacks)
09:40AM	Q3 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
01:14AM	The Exact Sciences Corp (EXAS) Company: A Short SWOT Analysis (GuruFocus.com)
12:30AM	Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-01-23 06:06PM	Exact Sciences Corp (EXAS) Reports 20% Revenue Increase in Q3 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Third-Quarter 2023 Results (PR Newswire)
06:00AM	Exact Sciences to participate in November investor conferences (PR Newswire)
Oct-31-23 05:20PM	15 Best ARK Stocks To Buy Now (Insider Monkey)
11:25AM	MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More (Zacks)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baranick Brian	EVP, GM., Precision Oncology	Apr 02 '24	Sale	79.43	924	73,393	13,171	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Apr 01 '24	Sale	70.00	2,000	140,000	71,787	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Mar 28 '24	Sale	70.00	2,000	140,000	73,787	Apr 01 04:30 PM
Conroy Kevin T	President and CEO	Mar 01 '24	Sale	59.32	8,271	490,636	1,299,496	Mar 04 08:38 PM
LEVANGIE DANIEL J	Director	Mar 01 '24	Sale	57.50	5,000	287,500	22,975	Mar 04 08:42 PM
Cunningham Everett	Chief Commercial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	46,179	Mar 04 08:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	10,933	Mar 04 08:40 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Mar 01 '24	Sale	59.32	2,323	137,800	14,095	Mar 04 08:36 PM
ORVILLE JACOB A	General Manager, Screening	Mar 01 '24	Sale	59.32	2,154	127,775	14,324	Mar 04 08:42 PM
Doyle James Edward	Director	Mar 01 '24	Sale	57.50	2,000	115,000	50,110	Mar 04 08:39 PM
Condella Sarah	EVP, Human Resources	Mar 01 '24	Sale	59.32	1,724	102,268	75,787	Mar 04 08:37 PM
Herriott James	General Counsel	Mar 01 '24	Sale	59.32	862	51,134	9,125	Mar 04 08:41 PM
Herriott James	General Counsel	Feb 29 '24	Option Exercise	0.00	1,890	0	9,987	Mar 04 08:41 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	13,345	Mar 04 08:40 PM
Cunningham Everett	Chief Commercial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	48,591	Mar 04 08:38 PM
Conroy Kevin T	President and CEO	Feb 29 '24	Option Exercise	0.00	18,143	0	1,307,767	Mar 04 08:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 29 '24	Option Exercise	0.00	4,724	0	16,418	Mar 04 08:36 PM
Condella Sarah	EVP, Human Resources	Feb 29 '24	Option Exercise	0.00	3,779	0	77,511	Mar 04 08:37 PM
ORVILLE JACOB A	General Manager, Screening	Feb 29 '24	Option Exercise	0.00	4,724	0	16,478	Mar 04 08:42 PM
Conroy Kevin T	President and CEO	Feb 27 '24	Sale	56.89	6,263	356,302	1,289,624	Feb 28 07:35 PM
Cunningham Everett	Chief Commercial Officer	Feb 27 '24	Sale	56.89	3,648	207,535	43,300	Feb 28 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27 '24	Sale	56.89	2,710	154,172	8,054	Feb 28 07:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 27 '24	Sale	56.89	2,027	115,316	11,694	Feb 28 07:34 PM
Condella Sarah	EVP, Human Resources	Feb 27 '24	Sale	56.89	1,880	106,953	73,732	Feb 28 07:35 PM
ORVILLE JACOB A	General Manager, Screening	Feb 27 '24	Sale	56.89	1,879	106,896	11,754	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 27 '24	Sale	56.89	784	44,602	8,097	Feb 28 07:38 PM
ORVILLE JACOB A	General Manager, Screening	Feb 26 '24	Option Exercise	0.00	3,954	0	13,633	Feb 28 07:38 PM
Cunningham Everett	Chief Commercial Officer	Feb 26 '24	Option Exercise	0.00	7,678	0	46,948	Feb 28 07:37 PM
Herriott James	General Counsel	Feb 26 '24	Option Exercise	0.00	1,648	0	8,881	Feb 28 07:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 26 '24	Option Exercise	0.00	5,701	0	10,764	Feb 28 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 26 '24	Option Exercise	0.00	3,954	0	75,612	Feb 28 07:35 PM
Conroy Kevin T	President and CEO	Feb 26 '24	Option Exercise	0.00	13,181	0	1,295,887	Feb 28 07:35 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 26 '24	Option Exercise	0.00	3,954	0	13,721	Feb 28 07:34 PM
Conroy Kevin T	President and CEO	Feb 23 '24	Option Exercise	13.96	102,837	1,435,605	1,344,266	Feb 26 05:00 PM
Condella Sarah	EVP, Human Resources	Feb 23 '24	Sale	59.72	1,021	60,974	71,658	Feb 26 05:00 PM
Conroy Kevin T	President and CEO	Feb 22 '24	Sale	59.78	11,565	691,356	1,241,429	Feb 23 07:59 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 22 '24	Sale	59.78	1,351	80,763	5,063	Feb 23 08:01 PM
Cunningham Everett	Chief Commercial Officer	Feb 22 '24	Sale	59.78	1,350	80,703	39,270	Feb 23 08:00 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 22 '24	Sale	59.78	1,093	65,340	9,767	Feb 23 07:57 PM
ORVILLE JACOB A	General Manager, Screening	Feb 22 '24	Sale	59.78	1,013	60,557	9,679	Feb 23 08:03 PM
Condella Sarah	EVP, Human Resources	Feb 22 '24	Sale	59.78	1,013	60,557	72,679	Feb 23 07:57 PM
COWARD D SCOTT	Director	Feb 22 '24	Sale	59.78	663	39,634	44,493	Feb 23 07:59 PM
Herriott James	General Counsel	Feb 22 '24	Sale	59.78	291	17,396	7,233	Feb 23 08:02 PM
Conroy Kevin T	President and CEO	Feb 21 '24	Sale	61.50	4,975	305,962	1,229,756	Feb 22 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 21 '24	Sale	61.50	1,493	91,820	3,703	Feb 22 07:38 PM
Condella Sarah	EVP, Human Resources	Feb 21 '24	Sale	61.50	1,079	66,358	71,658	Feb 22 07:36 PM
ORVILLE JACOB A	General Manager, Screening	Feb 21 '24	Sale	61.50	1,078	66,297	8,658	Feb 22 07:40 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 21 '24	Sale	61.50	895	55,042	8,826	Feb 22 07:36 PM
COWARD D SCOTT	Director	Feb 21 '24	Sale	61.50	706	43,419	43,122	Feb 22 07:38 PM
Herriott James	General Counsel	Feb 21 '24	Sale	61.50	415	25,522	6,943	Feb 22 07:39 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 20 '24	Option Exercise	0.00	3,112	0	5,196	Feb 22 07:38 PM
Conroy Kevin T	President and CEO	Feb 20 '24	Option Exercise	0.00	10,374	0	1,234,731	Feb 22 07:37 PM
COWARD D SCOTT	Director	Feb 20 '24	Option Exercise	0.00	2,248	0	43,828	Feb 22 07:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 20 '24	Option Exercise	0.00	1,729	0	9,721	Feb 22 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 20 '24	Option Exercise	0.00	2,248	0	72,737	Feb 22 07:36 PM
Herriott James	General Counsel	Feb 20 '24	Option Exercise	0.00	864	0	7,358	Feb 22 07:39 PM
ORVILLE JACOB A	General Manager, Screening	Feb 20 '24	Option Exercise	0.00	2,248	0	9,736	Feb 22 07:40 PM
Conroy Kevin T	President and CEO	Feb 15 '24	Sale	61.43	14,791	908,611	1,224,357	Feb 16 06:22 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 15 '24	Sale	61.43	1,888	115,980	2,084	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 15 '24	Sale	61.43	1,376	84,528	41,580	Feb 16 06:23 PM
ORVILLE JACOB A	General Manager, Screening	Feb 15 '24	Sale	61.43	966	59,341	7,488	Feb 16 06:26 PM
Condella Sarah	EVP, Human Resources	Feb 15 '24	Sale	61.43	965	59,280	70,489	Feb 16 06:21 PM
Herriott James	General Counsel	Feb 15 '24	Sale	61.43	421	25,862	6,494	Feb 16 06:25 PM
Conroy Kevin T	President and CEO	Feb 14 '24	Option Exercise	0.00	31,133	0	1,239,148	Feb 16 06:22 PM
Condella Sarah	EVP, Human Resources	Feb 14 '24	Option Exercise	0.00	2,031	0	71,454	Feb 16 06:21 PM
Herriott James	General Counsel	Feb 14 '24	Option Exercise	0.00	883	0	6,915	Feb 16 06:25 PM
ORVILLE JACOB A	General Manager, Screening	Feb 14 '24	Option Exercise	0.00	2,031	0	8,454	Feb 16 06:26 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 14 '24	Option Exercise	0.00	3,972	0	3,972	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 14 '24	Option Exercise	0.00	3,972	0	42,956	Feb 16 06:23 PM
Condella Sarah	EVP, Human Resources	Jan 02 '24	Sale	73.50	2,000	147,000	69,423	Jan 04 05:19 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Jan 02 '24	Sale	73.50	879	64,606	7,992	Jan 04 05:17 PM
Condella Sarah	EVP, Human Resources	Dec 14 '23	Sale	70.00	2,000	140,000	71,423	Dec 18 07:49 PM
Cunningham Everett	Chief Commercial Officer	Oct 12 '23	Sale	66.49	13,007	864,835	37,909	Oct 13 07:59 PM
Cunningham Everett	Chief Commercial Officer	Oct 11 '23	Option Exercise	0.00	27,504	0	50,916	Oct 13 07:59 PM
Condella Sarah	EVP, Human Resources	Sep 01 '23	Sale	84.36	4,500	379,620	75,814	Sep 06 04:04 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Aug 21 '23	Sale	82.92	30,210	2,505,013	0	Aug 23 04:08 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 07 '23	Sale	85.04	1,350	114,804	8,871	Aug 08 04:09 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 04 '23	Option Exercise	0.00	2,712	0	10,221	Aug 08 04:09 PM
Doyle James Edward	Director	Jul 27 '23	Sale	97.42	2,000	194,840	52,110	Jul 28 04:06 PM
Herriott James	General Counsel	Jul 19 '23	Sale	100.00	1,300	130,000	5,964	Jul 21 04:04 PM
Zanotti Katherine S	Director	Jun 09 '23	Sale	90.51	3,027	273,974	64,629	Jun 12 04:17 PM
Doyle James Edward	Director	Jun 09 '23	Sale	90.51	1,402	126,895	54,110	Jun 12 04:29 PM
Herriott James	General Counsel	Jun 08 '23	Sale	90.00	1,300	117,000	7,264	Jun 12 04:14 PM
Doyle James Edward	Director	May 26 '23	Sale	80.62	2,000	161,240	51,913	May 31 04:13 PM
Condella Sarah	EVP, Human Resources	May 10 '23	Sale	80.00	6,087	486,960	80,314	May 12 04:11 PM
ORVILLE JACOB A	General Manager, Screening	May 10 '23	Sale	80.00	5,000	400,000	6,423	May 12 04:09 PM
Herriott James	General Counsel	May 10 '23	Sale	79.85	1,300	103,805	8,564	May 12 04:07 PM
Condella Sarah	EVP, Human Resources	May 01 '23	Sale	63.78	1,000	63,780	86,401	May 03 04:04 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ESPR

Esperion Therapeutics Inc.

EXAS

Exact Sciences Corp.

Upgrade your FINVIZ experience